510(k) device
InSure ONE
Enterix, Inc. · Reagent, Occult Blood (KHE, Class II) · First FDA decision Oct 5, 2017, newest Oct 5, 2017Colorectal cancer and polypsGastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
5
Naming "InSure ONE"
MAUDE reports
0
Brand "InSure ONE", since 2015
PubMed studies
0
Mentioning "InSure ONE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing InSure ONE
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- InSure ONE510(k)
K170548 · Decided Oct 5, 2017 · 223 days after receipt
Device type: Reagent, Occult Blood (KHE) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Fecal Occult Blood TestNational determinationOn the books190.34Updated Oct 1, 2026
- Screening Immunoassay Fecal-Occult Blood TestNational analysisReview closedCAG-00180NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "InSure ONE", any status and sponsor, newest update first.
- Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPCPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT04725396 · 132 participants · Start Apr 20, 2021 · Primary completion Oct 15, 2025
Device: Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).; Conventional Mandibular Reconstruction (MR without PVP) · For: Oropharynx Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma
Sites: Bordeaux, France; Caen, France; Lille, France · 10 sites in all
Cairo UniversityAcademic, hospital or other
NCT04539210 · 12 participants (planned) · Start Sep 2020 · Primary completion Jan 2022
Device: Electric Welded Metal Framework · For: Patient Satisfaction; Maintenance
Sites: Cairo, Egypt
- Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDSPivotal-lookingCompleted
Catholic University of the Sacred HeartAcademic, hospital or other
NCT02482766 · 206 participants · Start Nov 2015 · Primary completion Sep 2018
Device: Ventilator for High-frequency Oscillatory Ventilation (HFOV); Nasal Continuous Positive Airway Pressure (nCPAP) · For: Respiratory Distress Syndrome; Hyaline Membrane Disease
Sites: Ancona, Italy; Bari, Italy; Bologna, Italy · 33 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "InSure ONE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code KHE
30 reports: 27 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0725-2026 · Started Sep 17, 2025 · Posted by FDA Nov 28, 2025
Reason given: InSure ONE failed sensitivity testing when used with Test Card Lot T241102, which may result in false negative results.
Cause as FDA categorized it: Under Investigation by firm · Device type: Reagent, Occult Blood (KHE)
Z-0590-2021 · Started Oct 8, 2020
Reason given: Product does not meet internal testing criterion; use of the product may result in a potential false positive test result and may lead to patients undergoing unnecessary follow-up diagnostic procedure, i.e., colonoscopy or sigmoidoscopy
Cause as FDA categorized it: Under Investigation by firm · Device type: Reagent, Occult Blood (KHE)
Published research
The most relevant PubMed records for "InSure ONE"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code KHE.
- Instant-View Fecal Occult Blood (Fob) Rapid TestAlfa Scientific Designs, Inc. · 510(k) 2007
- Instant-view-PLUS immunochemical Fecal Occult Blood TestAlfa Scientific Designs, Inc. · 510(k) 2018
- hema-screen SPECIFIC GoldImmunostics Inc. · 510(k) 2017
- Wondfo One Step Fecal Occult Blood (FOB) TestGuangzhou Wondfo Biotech Co., Ltd. · 510(k) 2017
- hema-screen ER XCEL Enhanced Readability Fecal Occult Blood TestImmunostics Inc. · 510(k) 2017
- OC-Light S FITEiken Chemical Co., Ltd. · 510(k) 2015
- Osom Ifob 25 Test and Patient Collection Kit Osom Ifob Control Kit Osom Ifob 50 Test KitSEKISUI Diagnostics, LLC · 510(k) 2012
- Ind One Step Occult Blood (Fob) TestInd Diagnostics, Inc. · 510(k) 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.